Searched for
GBR 900
Glenmark opens new manufacturing facility in SwitzerlandGlenmark Pharmaceuticals opened a new manufacturing facility in Switzerland for supply of clinical trial material.- Glenmark Pharmaceuticals's monoclonal antibody for pain entering human trialsGBR 900 is a monoclonal antibody for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor (NGF).
- We anticipate margins between 22% to 23% for the full year: Glenn Saldanha, Glenmark Ltd.Glenn Saldanha, Chairman and Managing Director, Glenmark Ltd., in an interview with ET Now, speaks about the company’s performance in the q...
- Glenmark gets $25 mn from Sanofi as final upfront paymentGlenmark Pharmaceuticals today said it has received Rs 110 crore from Sanofi, as second tranche of oulicensing fee for a deal with French d...
- Glenmark receives $25 mn from Sanofi as upfront paymentFollowing that clearance, the deal has now become effective and Glenmark has also received the first upfront payment of USD 25 million, it ...
- Failures and doubting investors have not dissuaded Glenmark Pharma's Glenn SaldanhaGlenmark has netted over $200 million in milestone and upfront payments while it has spent about $120-130 million on research.
- Glenmark Pharma in $613-million licensing deal with SanofiGlenmark Pharmaceuticals has licensed a new biotech drug to France's Sanofi which has the potential to generate revenues of $613 million or...
Load More- Glenmark gets $25 mn from Sanofi as final upfront payment